Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01515566 · ClinicalTrials.gov registry record · Phase 1
Breakthrough Dyspnea Fentanyl Study in Cancer Patients
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01515566: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01515566 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01515566, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if fentanyl given under the skin can reduce shortness of breath in cancer patients. Researchers also want to learn if it can help to improve your physical function. In this study, fentanyl will be compared to a placebo. Fentanyl is commonly used for treatment of cancer pain. It is believed to help patients with their shortness of breath as well. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
Primary Outcome
Retention rate is defined as the percentage of subjects able to complete the study.
Interventions
- OTHER Placebo
- BEHAVIORAL Questionnaires
- DRUG Fentanyl
- OTHER Walking Tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
What the finished NCT01515566 record still lists
NCT01515566 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01515566 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01515566 about?
NCT01515566 is a clinical study titled "Breakthrough Dyspnea Fentanyl Study in Cancer Patients". The goal of this clinical research study is to learn if fentanyl given under the skin can reduce shortness of breath in cancer patients. Researchers also want to learn if it can help to improve your physical function. In this study, fentanyl will be compared to a placebo. Fentanyl is commonly used ...
What is the current status of trial NCT01515566?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2012-04. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01515566?
The interventions under investigation include: Placebo (OTHER), Questionnaires (BEHAVIORAL), Fentanyl (DRUG), Walking Tests (OTHER).
Who is sponsoring clinical trial NCT01515566?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01515566's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia